AbbVie (ABBV) Depreciation & Amortization (CF) (2012 - 2026)

AbbVie (ABBV) has 15 years of Depreciation & Amortization (CF) data on file, last reported at $188.0 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 3.87% year-over-year to $188.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $769.0 million (up 0.92% YoY) and the FY2025 annual result came in at $762.0 million, changed 0.26% from the prior year.
• Depreciation & Amortization (CF) declined to $188.0 million in Q1 2026 per ABBV's latest filing, from $203.0 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $206.0 million in Q4 2024 and bottomed at $179.0 million in Q1 2023.
• The 5-year median for Depreciation & Amortization (CF) is $190.0 million (2023), against an average of $190.8 million.
• Peak annual rise in Depreciation & Amortization (CF) reached 13.29% in 2022, while the deepest fall reached 18.83% in 2022.
• Tracing ABBV's Depreciation & Amortization (CF) over 5 years: stood at $196.0 million in 2022, then decreased by 4.59% to $187.0 million in 2023, then increased by 10.16% to $206.0 million in 2024, then decreased by 1.46% to $203.0 million in 2025, then fell by 7.39% to $188.0 million in 2026.
• Per Business Quant, the three latest ABBV Depreciation & Amortization (CF) figures stand at $188.0 million (Q1 2026), $203.0 million (Q4 2025), and $192.0 million (Q3 2025).

Peer Comparison